Another “Biosimilar” Milestone: FDA Tentatively Approves Lilly/BI Copy Of Lantus
This article was originally published in RPM Report
Executive Summary
It isn’t a 351K pathway drug, but it does set up an interesting comparison for sponsors using the formal biosimilar pathway compared to the 505(b)(2) NDA route.